Cytheris expands interleukin trials for hepatitis C
This article was originally published in Scrip
Cytheris has begun an additional clinical trial with its main pipeline project CYT107, this time looking at the glycosylated recombinant human interleukin-7 molecule as add-on immunotherapy for chronic hepatitis C virus (HCV) patients unresponsive to standard combination treatment.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.